MX2019010733A - Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. - Google Patents

Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Info

Publication number
MX2019010733A
MX2019010733A MX2019010733A MX2019010733A MX2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A MX 2019010733 A MX2019010733 A MX 2019010733A
Authority
MX
Mexico
Prior art keywords
disease
methods
ulcerative colitis
crohn
jak1 inhibitor
Prior art date
Application number
MX2019010733A
Other languages
English (en)
Spanish (es)
Inventor
Y Sheikh Ahmad
M Mulhern Mathew
T Mayer Peter
Jayanth Jayanthy
D Allian Ayman
J Marroum Patrick
B Borchardt Thomas
B Thakkar Roopal
JUNGERWIRTH Steven
Paula MACHADO DE LA CERDA Ana
M Robinson Anne
Jeffrey V Enejosa Jose
L Pangan Aileen
Eslam Mohamed Mohamed-
Othman Ahmed
KLÜNDER Ben
Lars Nordstrom Fredrik
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61750557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2019010733A publication Critical patent/MX2019010733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019010733A 2017-03-09 2018-03-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. MX2019010733A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US201762593629P 2017-12-01 2017-12-01
PCT/US2018/021800 WO2018165581A1 (en) 2017-03-09 2018-03-09 Methods of treating crohn's disease and ulcerative colitis

Publications (1)

Publication Number Publication Date
MX2019010733A true MX2019010733A (es) 2019-11-01

Family

ID=61750557

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010733A MX2019010733A (es) 2017-03-09 2018-03-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2022015499A MX2022015499A (es) 2017-03-09 2019-09-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015499A MX2022015499A (es) 2017-03-09 2019-09-09 Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.

Country Status (9)

Country Link
US (3) US20190046527A1 (https=)
EP (2) EP3592353A1 (https=)
JP (3) JP2020510016A (https=)
CN (2) CN120661512A (https=)
AU (2) AU2018230500B2 (https=)
BR (1) BR112019018576A2 (https=)
MX (2) MX2019010733A (https=)
TW (2) TWI851536B (https=)
WO (2) WO2018165581A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
CN120661512A (zh) 2017-03-09 2025-09-19 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法
US20220002306A1 (en) * 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
WO2020115212A1 (en) * 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110101669A (zh) * 2019-06-11 2019-08-09 南京新酶合医药科技有限公司 一种乌帕替尼颗粒的生产工艺
CA3303671A1 (en) 2019-09-30 2026-03-31 Abbvie Inc. Treating spondyloarthritic and psoriatic conditions with upadacitinib
CN114206878B (zh) 2020-07-08 2024-04-19 苏州科睿思制药有限公司 乌帕替尼的晶型及其制备方法和用途
MX2023007741A (es) * 2020-12-29 2023-09-15 Abbvie Inc Formulaciones de upadacitinib de liberacion prolongada.
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
MX2024008557A (es) * 2022-01-13 2024-09-11 Abbvie Inc Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos.
CA3248817A1 (en) * 2022-01-20 2023-07-27 Renata Pharmaceutical (Ireland) Limited Extended-release pharmaceutical composition of Upadacitinib
WO2024052820A1 (en) * 2022-09-09 2024-03-14 Intas Pharmaceuticals Ltd. Upadacitinib formulation
US12531141B2 (en) * 2023-01-17 2026-01-20 Children's Hospital Medical Center Model-informed precision dosing systems for treatment of inflammatory bowel disease
WO2025149974A1 (en) * 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
CN120699157B (zh) * 2025-07-16 2025-12-16 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
TW200801008A (en) 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
WO2008063287A2 (en) 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
CA2687130C (en) 2007-05-07 2017-10-03 Evonik Roehm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
JP2011515438A (ja) 2008-03-28 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸ペレットの製造方法
JP5748659B2 (ja) 2008-06-10 2015-07-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
WO2011013082A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
PE20121336A1 (es) 2009-12-01 2012-11-03 Abbvie Inc Nuevos compuestos triciclicos
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
JP2017529334A (ja) 2014-08-27 2017-10-05 アッヴィ・インコーポレイテッド 局所製剤
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3554485B9 (en) * 2016-12-14 2023-09-27 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
CN120661512A (zh) * 2017-03-09 2025-09-19 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法

Also Published As

Publication number Publication date
WO2018165581A1 (en) 2018-09-13
TW201840318A (zh) 2018-11-16
US20220233527A1 (en) 2022-07-28
CN110392572A (zh) 2019-10-29
WO2022178492A1 (en) 2022-08-25
US20210361647A1 (en) 2021-11-25
EP4487908A2 (en) 2025-01-08
JP2024009963A (ja) 2024-01-23
JP2026041823A (ja) 2026-03-10
AU2018230500A1 (en) 2019-09-19
US11607411B2 (en) 2023-03-21
TW202517269A (zh) 2025-05-01
AU2018230500B2 (en) 2024-03-07
EP3592353A1 (en) 2020-01-15
CN120661512A (zh) 2025-09-19
MX2022015499A (es) 2023-01-24
AU2024203642A1 (en) 2024-06-20
TWI851536B (zh) 2024-08-11
AU2024203642B2 (en) 2025-08-21
JP2020510016A (ja) 2020-04-02
CA3052873A1 (en) 2018-09-13
BR112019018576A2 (pt) 2020-04-14
EP4487908A3 (en) 2025-01-15
US20190046527A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
JP2013155188A5 (https=)
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112018012237A2 (pt) conjugados oligonucleotídeos-peptídeos
MX2016012052A (es) Dimetilfumarato y regimenes de vacunacion.
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
BR112016029437A2 (pt) métodos para tratamento e prevenção de doenças de instabilidade vascular
MX2022004449A (es) Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia.
PH12017500617B1 (en) Dosage regimen for pegylated interferon
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
Fang et al. Comparison between albendazole and triclabendazole against Fasciola gigantica in human
Estenkova et al. About the SPA and resort-based treatment of the patients with oncological diseases
WANG et al. Therapeutic effect of creatine phosphate in early diastolic dysfunction
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
UA97450U (en) Method of fetal neuroprotection
MX2024011316A (es) Tratamiento del glioma de bajo grado con mirdametinib
Fernandez-Miranda Metabolic syndrome and sedation: 2 case reports
RU2014111152A (ru) Способ лечения детей с хроническим пиелонефритом при экологоотягощенном анамнезе